|DB00252||Phenytoin||For the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.|
|DB00313||Valproic Acid||**Indicated** for:[Label]
1) Use as monotherapy or adjunctive therapy in the management of complex partial seizures and simple or complex absence seizures.
2) Adjunctive therapy in the management of multiple seizure types that include absence seizures.
3) Prophylaxis of migraine headaches.
4) Acute management of mania associated with bipolar disorder.
**Off-label** uses include:
1) Maintenance therapy for bipolar disorder.[A177919]
2) Treatment for acute bipolar depression.[A177928,A177931,A177934]
3) Emergency treatment of status epilepticus.[A177955]|
|DB00347||Trimethadione||Used in the control of absence (petit mal) seizures that are refractory to treatment with other medications.|
|DB00532||Mephenytoin||For the treatment of refractory partial epilepsy.|
|DB00555||Lamotrigine||Indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures/primary generalized tonic-clonic seizures/generalized seizures of Lennox-Gastaut syndrome [FDA Label].
Indicated for conversion to monotherapy in adults (≥16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED)[FDA Label].
Indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥18 years of age) treated for acute mood episodes with standard therapy [FDA Label].|
|DB00593||Ethosuximide||For the treatment of petit mal epilepsy.|
|DB00754||Ethotoin||For the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures.|
|DB00776||Oxcarbazepine||For use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy and as adjunctive therapy in the treatment of partial seizures in children ages 4-16 with epilepsy.|
|DB00794||Primidone||Primidone is commonly indicated for the management of grand mal, psychomotor, and focal epileptic seizures [L4645, FDA Label]. In addition, it has also been studied and utilized as an effective management of essential tremor [A39414, A39415, L4645].|
|DB00906||Tiagabine||For the treatment of partial seizures|
|DB00909||Zonisamide||For use as adjunctive treatment of partial seizures in adults with epilepsy.|
|DB00949||Felbamate||For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.|
|DB00996||Gabapentin||For the management of postherpetic neuralgia in adults and as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy.|
|DB01080||Vigabatrin||For use as an adjunct in treatment resistant epilepsy, refractory complex partial seizures, and secondary generalized seizures. It is also used as monotherapy in infantile spasms in West syndrome.|
|DB01320||Fosphenytoin||For the control of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery. It can also be substituted, short-term, for oral phenytoin.|
|DB05246||Methsuximide||For the control of absence (petit mal) seizures that are refractory to other drugs.|
|DB06218||Lacosamide||Lacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old. Injection is indicated for short term use when oral therapy is not feasible. |
|DB08872||Gabapentin enacarbil||For the treatment of adult Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).|